National

UN chief calls on Israel to reverse ban on international aid groups

Jan 04, 2026

Washington DC [US], January 4: UN Secretary General Antonio Guterres on Friday urged Israel to reverse its decision to revoke the operating licences of dozens of international aid organizations.
The move would further worsen the humanitarian crisis facing Palestinians, Guterres warned, according to his spokesman Stephane Dujarric.
Israeli authorities have demanded that aid groups register from Thursday, January 1, a requirement many organizations reject as unlawful. According to the Israeli Ministry of Foreign Affairs, they must cease their activities by March. This also affects operations in the Gaza Strip, largely destroyed by the war between Israel and the Palestinian Islamist militia Hamas.
A total of 37 organizations are affected, including Doctors Without Borders (MSF) and Oxfam.
In a joint statement issued by Oxfam on behalf of 53 international non-governmental organizations, the groups called on Israel to "immediately halt deregistration proceedings and lift measures obstructing humanitarian assistance." "We urge donor governments to use all available leverage to secure the suspension and reversal of these actions," the statement added.
Israel's threat to deny registration to aid groups is "a cynical and calculated attempt to prevent organizations from providing services in Gaza and the West Bank," Doctors Without Borders said in a separate statement, adding that Israel was violating its obligations under international humanitarian law.
Organizations are also reportedly required to disclose confidential information about Palestinian employees and to dismiss staff upon request without being given reasons. The involvement of a party to the conflict in personnel checks is seen as a violation of humanitarian principles such as neutrality and independence. Offers for review by neutral bodies have so far been rejected.
Source: Qatar Tribune

More news

Sirolimus-Coated Balloon Matches Drug-Eluting Stent at One Year in Large International TRANSFORM II Trial

Tampa (Florida) [US], November 2: Sirolimus-coated balloon (SCB) strategy was non-inferior to contemporary everolimus-eluting stents (EES) for Target Lesion Failure (TLF) at 12 months in patients with de novo coronary artery disease. These are the results of the TRANSFORM II randomised trial, presented today as a Late-Breaking Clinical Trial at TCT 2026 and accepted in The Lancet which confirm how MagicTouch Sirolimus Coated Balloon (Concept Medical) matches contemporary best in class stent. Late-breaking results presented at TCT 2026 show an implant-free strategy with MagicTouch Sirolimus Coated Balloon is non-inferior to everolimus-eluting in de novo coronary artery disease.

Nov 02, 2026